ARVO 2018: Dr. Steve Rose Reports on CRISPR/Cas9 for Inherited Retinal Diseases

FFB’s own Dr. Steve Rose, chief scientific officer, reviews our commitment to funding and exploring CRISPR/Cas9 gene editing for inherited retinal disease in the video below. FFB currently funds CRISPR/Cas9 projects at four institutions:
  • Johns Hopkins University (retinitis pigmentosa caused by the P23H mutation in RHO)
  • Columbia University (RP caused by the D190N mutation in RHO)
  • Massachusetts Eye and Ear Infirmary (RP caused by a mutation in RP1)
  • UCLA (Usher syndrome 1B caused by a mutation in MYO7A)
Want to learn more about the benefits of CRISPR/Cas9? Check out: A Cut-and-Paste Approach to Fixing Retinal-Disease Genes  

https://www.lvcenter4sight.com/arvo-2018-dr-steve-rose-reports-on-crispr-cas9-for-inherited-retinal-diseases/

Comments

Post a Comment

Popular posts from this blog

Week in review: Pay raise, Von’s Vision, gonio-<em>what?</em>

Image
APR 13, 2018 By Anni Griswold Comprehensive Ophthalmology, Cornea/External Disease, Glaucoma, Pediatric Ophth/Strabismus Above: The GonioPEN (Credit: Nanyang Technological University) A weekly roundup of ophthalmic news from around the web. Ophthalmologists earn more than the average physician , and their salaries are on the rise (+3% over the last year, to be precise). Eye docs will earn a mean $375,000 this year—more than the physician average of $299,000, but well below a typical plastic surgeon’s paycheck. See for yourself in Medscape’s 2018 Physician Compensation Report . Medscape A special supplement to USA Today will highlight the work of Von Miller , a 28-year-old linebacker for the Denver Broncos and former Super Bowl MVP. Through his foundation, Von’s Vision, Miller connects thousands of underprivileged children in Denver with affordable, high-quality eye care. His interview will appear in the “Vision Health” campaign during World Glaucoma Week, available in pr...
Read more

Patch with Microneedles Could Replace Eye Injections

Image
Instead of getting eye injections, patients with serious eye diseases may be eligible for a contact lens-type patch. 1 Injections are often recommended for eye diseases such as Wet (advanced) Age-Related Macular Degeneration, macular edema, and glaucoma. The new patch is inserted painlessly like a contact lens. It delivers tiny microneedles containing medication. The microneedles are made from natural materials and dissolve over time, gradually releasing medicine. Patients would be more likely to stick with a regimen that does not involve eye injections. Eye Injections: Stick a Needle in My Eye Patients generally dread eye injections. Injections must be performed in a doctor’s office. Eye injections can be painful, and they are inconvenient. They can introduce infection. And they can damage the eye. Avastin, Eylea, and Lucentis are injectable medications that discourage new blood vessel growth. These anti-VEGF medicines are useful for advanced Macular Degeneration , Diabetic Retino...
Read more

Incidence of eyelid SCC appears to be rising

FEB 12, 2018 Oculoplastics/Orbit This retrospective study examined demographic risk factors for developing eyelid squamous cell carcinoma (SCC). Study design Using data from the National Cancer Registration and Analysis Service, investigators identified all cases of eyelid SCC in England between 2000 and 2014. Outcomes Over the 15-year study period, there were 4,022 patients with newly diagnosed SCC affecting the eyelid. The age-standardized number of reported cases of eyelid SCC rose approximately 2% per year over the study period. The risk for developing an eyelid SCC approximately doubled each decade after age 60. Men were at 1.9-times greater relative risk compared with women. The authors did not find any association between income quintile and risk of SCC. Limitations The cause for the increasing incidence of eyelid SCC was not studied. While age may represent one factor, others such as an increasing rate of patients receiving immunosuppression therapies may als...
Read more